Anika Therapeutics | ANIK - Sales Revenues


Anika Therapeutics reported $30.62M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Agenus USD 34.2M 3.97M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Integra LifeSciences USD 391.9M 43M Mar/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merit Medical Systems USD 381.9M 12M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Smith & Nephew USD 3.18B 353M Dec/2025
Stryker USD 6B 1.2B Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026
Zimmer Biomet Holdings USD 2.09B 150M Mar/2026